[Secondary prevention of ischaemic cardiopathy: are we doing it right?].
作者信息
Simó Cruzet E, Garrido Pérez M, Ureña Tapia M, Martí Company F, Avilés Fernández F J
出版信息
Aten Primaria. 2004 Jan;33(1):51-3. doi: 10.1016/s0212-6567(04)78880-0.
Abstract
摘要
相似文献
1
[Secondary prevention of ischaemic cardiopathy: are we doing it right?].
Aten Primaria. 2004 Jan;33(1):51-3. doi: 10.1016/s0212-6567(04)78880-0.
2
[Secondary prevention of ischaemic cardiopathy in a primary care center].
Aten Primaria. 2003 May 31;31(9):614-5. doi: 10.1016/s0212-6567(03)79227-0.
3
Prevention of cardiovascular ischemic events: high-risk and secondary prevention.
Circulation. 2003 Apr 22;107(15):2059-65. doi: 10.1161/01.CIR.0000067881.26274.BD.
4
[Secondary prevention of ischaemic cardiopathy in Spain. Quo vadis?].
Aten Primaria. 2006 Sep 30;38(5):257-9. doi: 10.1157/13092982.
5
[Life style and the prevention of ischemic cardiopathy].
Ann Ig. 1994 Mar-Apr;6(2):119-27.
6
7
[Ischaemic cardiopathy: do we practice secondary prevention in primary care?].
Aten Primaria. 2001 Jun 15;28(1):81-3. doi: 10.1016/s0212-6567(01)78901-9.
8
Secondary prevention of ischaemic cardiac events.
Clin Evid. 2002 Dec(8):129-68.
9
Secondary prevention of ischaemic cardiac events.
Clin Evid. 2002 Jun(7):124-60.
10
[The epidemiology and risk factors of ischemic cardiopathy].
Rev Esp Cardiol. 1995;48 Suppl 5:3-12.
引用本文的文献
1
Impact of Implementing a Dyslipidemia Management Guideline on Cholesterol Control for Secondary Prevention of Ischemic Heart Disease in Primary Care.
Int J Environ Res Public Health. 2020 Nov 19;17(22):8590. doi: 10.3390/ijerph17228590.
2
[Are we monitoring, in primary care, dyslipaemia in patients with ischaemic cardiopathy?].
Aten Primaria. 2007 Dec;39(12):675-6. doi: 10.1157/13113964.
本文引用的文献
1
[Secondary prevention of myocardial infarction and health-related quality of life].
Med Clin (Barc). 2002 Jun 8;119(1):9-12.
2
Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.
Lancet. 2001 Mar 31;357(9261):995-1001. doi: 10.1016/s0140-6736(00)04235-5.
3
[Secondary prevention of ischemic heart disease in primary care (PRESENCIAP)].
Aten Primaria. 2001 Jan;27(1):29-32. doi: 10.1016/S0212-6567(01)78769-0.
4
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
N Engl J Med. 1998 Nov 5;339(19):1349-57. doi: 10.1056/NEJM199811053391902.
5
6
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet. 1994 Nov 19;344(8934):1383-9.
7
Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction.
JAMA. 1988 Oct 14;260(14):2088-93.
Zotero 插件